Results 81 to 90 of about 757,481 (306)

An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. [PDF]

, 2019
Lessons learnedTKM-080301 showed a favorable toxicity profile at the studied dose.TKM-080301 targeting PLK1 through small interfering RNA mechanism did not demonstrate improved overall survival in patients with advanced hepatocellular carcinoma compared ...
Abou-Alfa, Ghassan K, Brown, Joanne, Chao, Tsu-Yi, Choi, Hye Jin, El Dika, Imane, Freilich, Bradley, Kelley, Robin K, Knox, Jennifer, Lim, Ho Yeong, Lin, Chia-Chi, Modiano, Manuel, Ryoo, Baek-Yeol, Yau, Thomas, Yong, Wei Peng, Yoon, Jung-Hwan   +14 more
core   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Multi-output prediction of dose–response curves enables drug repositioning and biomarker discovery

npj Precision Oncology
Drug response prediction is hampered by uncertainty in the measures of response and selection of doses. In this study, we propose a probabilistic multi-output model to simultaneously predict all dose–responses and uncover their biomarkers.
Juan-José Giraldo Gutierrez, Evelyn Lau, Subhashini Dharmapalan, Melody Parker, Yurui Chen, Mauricio A. Álvarez, Dennis Wang   +6 more
doaj   +1 more source

Open label, dose escalation trial of creatine monohydrate in pregnancy

Journal of the International Society of Sports Nutrition
Background Preclinical data demonstrates that creatine supplementation during pregnancy supports maternal and fetal energy homeostasis through periods of hypoxia, but its use in human pregnancy remains unexplored.
Madison Naidu, Deborah L de Guingand, Georgina Hunter, Nhi T Tran, Rod J Snow, Carl M Kirkpatrick, Stacey J Ellery, Kirsten R Palmer   +7 more
doaj   +1 more source

Efficacy of high-dose vs. low-dose intravitreal ganciclovir for cytomegalovirus retinitis: a systematic review and meta-analysis [PDF]

Journal of Yeungnam Medical Science
Background Intravitreal ganciclovir is widely used to achieve effective local antiviral concentrations for cytomegalovirus (CMV) retinitis; however, to our knowledge, standardized dosing strategies have not been established, and the reported regimens ...
Seongyong Jeong, Areum Jeong, Jae Rock Do, Yong Koo Kang, Min Sagong   +4 more
doaj   +1 more source

The pharmacodynamics of the p53-Mdm2 targeting drug Nutlin: the role of gene-switching noise. [PDF]

PLoS Computational Biology, 2014
In this work we investigate, by means of a computational stochastic model, how tumor cells with wild-type p53 gene respond to the drug Nutlin, an agent that interferes with the Mdm2-mediated p53 regulation.
Krzysztof Puszynski, Alberto Gandolfi, Alberto d'Onofrio   +2 more
doaj   +1 more source

A Bayesian time-to-event pharmacokinetic model for sequential phase I dose-escalation trials with multiple schedules

, 2020
Phase I dose-escalation trials constitute the first step in investigating the safety of potentially promising drugs in humans. Conventional methods for phase I dose-escalation trials are based on a single treatment schedule only.
Friede, Tim, Günhan, Burak Kürsad, Seroutou, Abdelkader, Weber, Sebastian   +3 more
core   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Identification and characterization of a phenyl-thiazolyl-benzoic acid derivative as a novel RAR/RXR agonist

Heliyon, 2019
Objective: To identify an agonist of RXRα and RARα with reduced undesired profiles of all-trans retinoic acid for differentiation-inducing therapy of acute promyelocytic leukemia (APL), such as its susceptibility to P450 enzyme, induction of P450 enzyme,
Chie Koshiishi, Takanori Kanazawa, Eric Vangrevelinghe, Toshiyuki Honda, Shinji Hatakeyama   +4 more
doaj   +1 more source

Deletion of the GABAA α2-subunit does not alter self dministration of cocaine or reinstatement of cocaine seeking [PDF]

, 2014
Rationale GABAA receptors containing α2-subunits are highly represented in brain areas that are involved in motivation and reward, and have been associated with addiction to several drugs, including cocaine.
A Agrawal, AC Barrett, B. Halbout, C Schwarzer, C. I. Dixon, CI Dixon, CI Dixon, CI Dixon, D. N. Stephens, DM Dick, DM Thompson, EM Weerts, G Brown, HC Fox, HJ Edenberg, HN Katz, HV Morris, HV Morris, J Covault, J Merrer Le, JD Salamone, JR Taylor, K Low, KL Conrad, LA Knackstedt, LJ Herberg, LM Reynolds, LO Bauer, M Filip, M Filip, MA Enoch, MA Enoch, MJ Thomas, ND Volkow, P Waelti, PA Broderick, PA Lind, R Keiflin, R Sinha, RA Wise, RW Keller Jr, S Erb, S Pirker, S Taverna, S Villafuerte, S. L. King, SA Kushner, SH Ahmed, SL Dewey, SS Negus, TE Robinson, TW Robbins, TW Robbins, TW Robbins, W Schultz, Y Kawaguchi   +55 more
core   +1 more source